Avadel Pharmaceuticals Plc (AVDL):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Avadel Pharmaceuticals Plc (AVDL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10085
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Avadel Pharmaceuticals Plc (Avadel), formerly Flamel Technologies SA is a specialty pharmaceutical company, which develops and commercializes drugs for allergy, asthma, central nervous system (CNS) (narcolepsy), pain, respiratory diseases and diabetes. The company’s products are built on its proprietary polymer-based technologies: Micropump, an oral sustained release microparticles platform, LiquiTime, a Micropump – derived platform for liquid oral products, Trigger Lock, a Micropump – derived platform that enables abuse-resistant modified and controlled release formulations and Medusa that enables controlled release of injectables. It sells its products in the US, France, and Ireland. The company operates in St. Louis, Missouri, and Charlotte in the US. Avadel is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals Plc (AVDL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Avadel Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 11
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Flamel Technologies Enters Into Product Partnership Agreement With Pharma Company 13
Merger 14
Flamel Technologies Merges with Avadel Pharma 14
Licensing Agreements 15
Cerecor to Enter into Licensing Agreement with Avadel Ireland 15
Avadel Pharma to Enter into Licensing Agreement with Serenity Pharma for Noctiva 16
Perrigo Enters into Licensing Agreement with Flamel Ireland 18
Tris Pharma And FSC Labs Enter Into Licensing Agreement For Karbinal ER 19
Equity Offering 20
Flamel to Raise USD13.1 Million in Private Placement of Shares 20
Flamel Technologies Completes Public Offering Of Shares For US$121 Million 21
Debt Offering 23
Avadel Pharma Raises USD143.8 Million in Private Placement of 4.5% Notes Due 2023 23
Flamel Technologies Completes Private Placement Of Notes Due 2017 For US$15 Million 24
Asset Transactions 25
Cerecor Acquires Pediatric Business from Avadel Pharma 25
Aytu BioScience Acquires Rights to Primsol from FSC Labs for USD1.8 Million 27
Recipharm Acquires Development and Manufacturing Facility from Flamel for USD13.2 Million 28
Acquisition 30
Flamel Technologies Acquires FSC Holdings 30
Flamel Technologies Acquires Eclat Pharma For US$12 Million 32
Avadel Pharmaceuticals Plc – Key Competitors 34
Avadel Pharmaceuticals Plc – Key Employees 35
Avadel Pharmaceuticals Plc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 38
Financial Announcements 38
Nov 05, 2018: Avadel Pharmaceuticals reports third quarter 2018 financial results 38
Aug 07, 2018: Avadel Pharmaceuticals reports second quarter 2018 financial results 40
May 02, 2018: Avadel Pharmaceuticals Reports First Quarter 2018 Results 42
Mar 08, 2018: Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Results 44
Nov 08, 2017: Avadel Pharmaceuticals Reports Third Quarter 2017 Results 45
Aug 08, 2017: Avadel Pharmaceuticals Reports Second Quarter 2017 Results 47
May 09, 2017: Avadel Pharmaceuticals Reports First Quarter 2017 Results 49
Mar 07, 2017: Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Results 50
Corporate Communications 52
Mar 22, 2018: Avadel Pharmaceuticals Announces Promotion of Gregory J. Divis to Chief Operating Officer 52
Mar 30, 2017: Avadel Pharmaceuticals Announces Planned Reduction of French Workforce 53
Jan 03, 2017: Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Commercial Officer 54
Clinical Trials 55
May 17, 2017: Avadel Pharmaceuticals Supports the Narcolepsy Network’s 5th Annual DREAM BIG Walk 55
Other Significant Developments 56
Dec 29, 2017: Avadel Pharmaceuticals Issues 2018 Corporate Outlook 56
Jan 05, 2017: Avadel Pharmaceuticals Provides 2017 Guidance and Business Update 58
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Avadel Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Avadel Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 11
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Flamel Technologies Enters Into Product Partnership Agreement With Pharma Company 13
Flamel Technologies Merges with Avadel Pharma 14
Cerecor to Enter into Licensing Agreement with Avadel Ireland 15
Avadel Pharma to Enter into Licensing Agreement with Serenity Pharma for Noctiva 16
Perrigo Enters into Licensing Agreement with Flamel Ireland 18
Tris Pharma And FSC Labs Enter Into Licensing Agreement For Karbinal ER 19
Flamel to Raise USD13.1 Million in Private Placement of Shares 20
Flamel Technologies Completes Public Offering Of Shares For US$121 Million 21
Avadel Pharma Raises USD143.8 Million in Private Placement of 4.5% Notes Due 2023 23
Flamel Technologies Completes Private Placement Of Notes Due 2017 For US$15 Million 24
Cerecor Acquires Pediatric Business from Avadel Pharma 25
Aytu BioScience Acquires Rights to Primsol from FSC Labs for USD1.8 Million 27
Recipharm Acquires Development and Manufacturing Facility from Flamel for USD13.2 Million 28
Flamel Technologies Acquires FSC Holdings 30
Flamel Technologies Acquires Eclat Pharma For US$12 Million 32
Avadel Pharmaceuticals Plc, Key Competitors 34
Avadel Pharmaceuticals Plc, Key Employees 35
Avadel Pharmaceuticals Plc, Subsidiaries 36

List of Figures
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Avadel Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Avadel Pharmaceuticals Plc (AVDL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lancer Systems L.P.:企業の戦略・SWOT・財務情報
    Lancer Systems L.P. - Strategy, SWOT and Corporate Finance Report Summary Lancer Systems L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Danville Materials Inc:医療機器:M&Aディール及び事業提携情報
    Summary Danville Materials Inc (Danville), a subsidiary of Inverness Graham Investments is a medical device company that manufactures dental equipment. The company provides posts, air abrasion, tin plating, adhesives, sand blasting, composites, air polishing, dust cabinets, microetcher, and IPR. It …
  • Marsh & McLennan Companies, Inc.:企業の戦略・SWOT・財務情報
    Marsh & McLennan Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Marsh & McLennan Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Vietnam Electricity:企業の戦略的SWOT分析
    Vietnam Electricity - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Silver Creek Midstream LLC:石油・ガス:M&Aディール及び事業提携情報
    Summary Silver Creek Midstream LLC (Silver Creek) is an independent midstream oil and gas company that acquires, develops and operates crude oil pipeline and storage assets. It offers crude oil gathering, transportation, storage, and terminalling services. The company operates crude oil gathering an …
  • Carpenter Co.:企業の戦略・SWOT・財務情報
    Carpenter Co. - Strategy, SWOT and Corporate Finance Report Summary Carpenter Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Catalyst Biosciences Inc:企業のM&A・事業提携・投資動向
    Catalyst Biosciences Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Catalyst Biosciences Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • OpGen Inc (OPGN)-医療機器分野:企業M&A・提携分析
    Summary OpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). The company’s clinical laboratory services include high resolution microbial sequence analysis, s …
  • Prakash Industries Ltd (PRAKASH):企業の財務・戦略的SWOT分析
    Summary Prakash Industries Ltd (PIL) is a power and steel company. The company’s business activities include mining, steel and power, plastic and wind power. Its mining business division offers explores, acquires and develops iron ore and coal properties. PIL’s steel and power business division prov …
  • Vectura Group Plc (VEC):医療機器:M&Aディール及び事業提携情報
    Summary Vectura Group Plc (Vectura) is a formulation and device business for inhaled airways products providing an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD) …
  • ARM Ltd.:企業の戦略・SWOT・財務分析
    ARM Ltd. - Strategy, SWOT and Corporate Finance Report Summary ARM Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Singulex Inc-医療機器分野:企業M&A・提携分析
    Summary Singulex Inc (Singulex) is a medical device company develops single molecule counting technology. The company provides Sgx clarity system, an in vitro diagnostics platform that provides high sensitivity next generation immunodiagnostics. Its proprietary SMC technology allows scientists and p …
  • Enea AB (ENEA):企業の財務・戦略的SWOT分析
    Summary Enea AB (Enea) is a technology company that provides software products, services and solutions. The company’s product portfolio consists of NFV virtualization platforms, operating systems, device and network management, traffic intelligence, 5g data management, access management and policy c …
  • P.T. Telekomunikasi Selular:企業の戦略・SWOT・財務情報
    P.T. Telekomunikasi Selular - Strategy, SWOT and Corporate Finance Report Summary P.T. Telekomunikasi Selular - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • National HealthCare Corp (NHC):製薬・医療:M&Aディール及び事業提携情報
    Summary National HealthCare Corp (NHC) is a health care service provider that offers home-care and assisted living services. The center offers rehabilitative care, skilled nursing, Alzheimer's and memory care, residential and assisted living, home care, hospice care and long term care insurance serv …
  • Avnet, Inc.:戦略・SWOT・企業財務分析
    Avnet, Inc. - Strategy, SWOT and Corporate Finance Report Summary Avnet, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Anadarko Petroleum Corp (APC):企業の財務・戦略的SWOT分析
    Anadarko Petroleum Corp (APC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • First Quantum Minerals Ltd:戦略・SWOT・企業財務分析
    First Quantum Minerals Ltd - Strategy, SWOT and Corporate Finance Report Summary First Quantum Minerals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Qantas Airways Ltd (QAN):企業の財務・戦略的SWOT分析
    Qantas Airways Ltd (QAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • nLife Therapeutics SL-製薬・医療分野:企業M&A・提携分析
    Summary nLife Therapeutics SL (nLife Therapeutics) is a biopharmaceutical company that discovers and develops proprietary neuronal specific oligonucleotides as therapeutic agents for the treatment of central nervous system disorders. Its lead candidate NLF-PD-1233 is a first in class oligonucleotide …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆